ClinicalTrials.gg
RecruitingNCT07701343Updated Oct 28, 2026

tACS for Working Memory in Schizophrenia

An interventional study of transcranial alternating current stimulation and sham stimulation in Schizophrenia and Working Memory, sponsored by Central South University. Recruiting at 1 site in China. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Central South University · Not applicable, Interventional, and Treatment

How we know

Updated Oct 28, 2026Start date movedPrimary outcomes revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 34 studies in Schizophrenia by Central South University — 10 open to participants now, 10 under way, 1 of them phase 3. Schizophrenia · Central South University.

Planned enrollment
26th of 28
30 · median 80
Started
2026
with 4 others
No phase
18 of 34
7 open now
Registered
32nd of 34
by date

Among the 34 studies in Schizophrenia by Central South University, this one is the 26th largest by planned enrollment of the 28 interventional ones that give a count, is one of 5 that started in 2026, is one of 18 with no phase, and was the 32nd registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

10 of the 34 studies in Schizophrenia by Central South University are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Schizophrenia by Central South University, or all of them as a file.
02

Study summary

This study is a randomized, single-blind, sham-controlled crossover trial enrolling 30 schizophrenia patients, each receiving one active and one sham tACS session (7-day washout), targeting P3/P4 at individual alpha frequency (2mA, 30min) during a working memory task, with accuracy and reaction time as primary outcomes, alongside EEG and neurophysiological measures, to test the efficacy and mechanisms of individualized alpha-tACS on working memory.

Read the detailed description

This study is a randomized, single-blind, sham-controlled, crossover exploratory trial that plans to enroll 30 inpatients with schizophrenia, randomized 1:1 into two groups, with all participants receiving one active and one sham tACS session in a crossover manner separated by a 7-day washout. Stimulation targets the parietal P3/P4 sites at individual alpha frequency, with an intensity of 2 mA and a duration of 30 minutes per session, delivered concurrently with a working memory task (SIRP). Primary outcomes are SIRP accuracy and reaction time, with concurrent task-state EEG recording, along with assessments of clinical symptoms, cognitive function, and neurophysiological markers including ASSR, MMN, and P300. The study aims to explore the efficacy and underlying neural mechanisms of individualized alpha-tACS in improving working memory in schizophrenia.

03

Conditions studied

  • Schizophrenia
  • Working Memory

Browse trials for

Keywords

  • Schizophrenia
  • Working Memory
  • Transcranial Alternating Current Stimulation
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18-50 years, meeting the , Fifth Edition (DSM-5) diagnostic criteria for schizophrenia, confirmed by the Structured Clinical Interview for DSM-5 (SCID-5).
  • Spatial span T-score \<40 on the MATRICS Consensus Cognitive Battery (MCCB).
  • Taking 1-2 antipsychotic medications, with stable dosage for at least 1 week prior to enrollment. No use of mood stabilizers, antidepressants, or excessive benzodiazepines (lorazepam equivalent >2 mg/day). The type and dosage of antipsychotic medications remain unchanged during the treatment period.
  • Impaired functioning in daily activities.
  • Willing to participate in this study and provide written .

Exclusion criteria

Exclusion Criteria:

  • Previously diagnosed with or comorbid any other mental disorder besides schizophrenia.
  • Presence of significant mood symptoms or substance use disorder (other than caffeine and/or tobacco).
  • Presence of any to transcranial alternating current stimulation (tACS).
  • Received other forms of electrical or magnetic stimulation therapy within 1 month prior to enrollment.
  • History or current presence of any major physical illness, neurological disorder, or traumatic brain injury that may affect brain structure or function.
  • Pregnant or breastfeeding women, or women planning to become pregnant during the study period.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
30 participants (estimated)

Study arms

  • Sham comparator
    sham group

    sham stimulation

    Device: sham stimulation

  • Experimental
    active group

    transcranial alternating current stimulation

    Device: transcranial alternating current stimulation

Interventions

  • Devicetranscranial alternating current stimulation

    For montage 1, active electrode at P3 (10-10 system), return electrodes at P1, P5, PO3, CP3. For montage 2, active electrode at P4, return electrodes at P2, P6, PO4, CP4. Conductive paste ensures impedance \<10 kΩ. Individual alpha frequency is used, calculated before each session from mean EEG at P3/P4 during SIRP task. Stimulation intensity is 2 mA (peak-to-zero) via electric field modeling. Stimulation is delivered during SIRP task, 30 min total per session (including 15s ramp-up/down), with continuous sine wave output.

  • Devicesham stimulation

    Sham stimulation provides only a 15-second ramp-up and ramp-down current at the beginning and end of each session to mimic the initial tingling or itching sensation on the scalp produced by real stimulation, but delivers no effective stimulation current during the main phase of the task period.

06

What researchers measure

Primary outcomes

  1. Working Memory Accuracy

    Assessment of task accuracy on the Sternberg Item Recognition Paradigm (SIRP). Participants are required to judge whether a probe stimulus belongs to a previously memorized set. The outcome is measured as the percentage of correct responses (0-100%) across all trials, with higher scores indicating better working memory performance.

    Time frame: Day 1 (baseline, before the first intervention, during the intervention, and within 15 minutes after the intervention); Day 9 (before the second intervention, during the intervention, and within 15 minutes after the intervention).

  2. Working Memory Reaction Time

    Assessment of response speed on the Sternberg Item Recognition Paradigm (SIRP). Participants are required to judge whether a probe stimulus belongs to a previously memorized set. The outcome is measured as the mean response latency for correct responses only, calculated from stimulus onset to the participant's button press, with shorter times indicating faster processing speed.

    Time frame: Day 1 (baseline, before the first intervention, during the intervention, and within 15 minutes after the intervention); Day 9 (before the second intervention, during the intervention, and within 15 minutes after the intervention).

Secondary outcomes

  1. Changes in MCCB Performance

    Assessment of cognitive function using the MATRICS Consensus Cognitive Battery (MCCB), a standardized cognitive assessment tool designed for schizophrenia and other neuropsychiatric conditions. The MCCB evaluates 9 cognitive domains: attention, information processing speed, verbal learning and memory, visual learning and memory, spatial working memory, reasoning and problem solving, social cognition, executive function, and fine motor skills. The overall cognitive composite score ranges from 20 to 100 (T-score), with higher scores indicating better cognitive performance.

    Time frame: Baseline, on the day after each of the two interventions

  2. Changes in Positive and Negative Symptom Scale (PANSS) Scores

    Scores range from 30 to 210, with higher scores indicating more severe positive and negative symptoms.

    Time frame: Before and one week after each of the two interventions.

  3. Changes in Scale for the Assessment of Negative Symptoms (SANS) Scores

    Scores range from 0 to 120; higher scores indicate more severe negative symptoms.

    Time frame: Before and one week after each of the two interventions.

  4. Changes in Calgary Depression Scale for Schizophrenia (CDSS) Scores

    Scores range from 0 to 27; higher scores indicate more severe affective symptoms.

    Time frame: Before and one week after each of the two interventions.

  5. Changes in Brain Function

    Functional magnetic resonance imaging (fMRI), based on blood oxygen level-dependent (BOLD) contrast, can detect changes in blood oxygenation and analyze changes in brain function after intervention.

    Time frame: Baseline, on the day after each of the two interventions.

  6. Changes in Neuroelectrophysiological Signals

    Changes in neuroelectrophysiological signals are collected through task-based electroencephalography (EEG).

    Time frame: Baseline, 30 minutes after each of the two interventions.

  7. Changes in 40Hz Auditory Steady-State Response (40Hz-ASSR)

    The 40Hz auditory steady-state response recorded by EEG, including evoked power and inter-trial phase coherence, will be measured. The unit of measurement for evoked power is μV², and for coherence is unitless.

    Time frame: Baseline, 30 minutes after each of the two interventions.

  8. Changes in Mismatch Negativity (MMN)

    Mismatch negativity amplitude recorded by EEG using an oddball paradigm will be measured. The unit of measurement is microvolts (μV).

    Time frame: Baseline, 30 minutes after each of the two interventions.

  9. Changes in P300 Event-Related Potential

    P300 amplitude recorded by EEG using an oddball paradigm will be measured. The unit of measurement is microvolts (μV).

    Time frame: Baseline, 30 minutes after each of the two interventions.

  10. Hallucination Visual Analog Scale

    Assessment of acute post-intervention changes in hallucination severity using a patient-rated visual analog scale (VAS). The scale consists of a 0-100 mm horizontal line, on which participants mark their current symptom severity. The distance (in millimeters) from the left anchor ("no symptoms") to the participant's mark is measured with a ruler. This scale serves as a supplementary measure to the PANSS to capture immediate symptom changes following each intervention. Scores range from 0 to 100 mm, with higher scores indicating more severe hallucinations .

    Time frame: Within 15 minutes before and after completion of Session 1; within 15 minutes before and after completion of Session 2.

  11. Delusion Visual Analog Scale

    Assessment of acute post-intervention changes in state paranoia severity using a patient-rated visual analog scale (VAS). The scale consists of a 0-100 mm horizontal line, on which participants mark their current symptom severity. The distance (in millimeters) from the left anchor ("no symptoms") to the participant's mark is measured with a ruler. This scale serves as a supplementary measure to the PANSS to capture immediate symptom changes following each intervention. Scores range from 0 to 100 mm, with higher scores indicating more severe state paranoia .

    Time frame: Within 15 minutes before and after completion of Session 1; within 15 minutes before and after completion of Session 2.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Oct 2026, 0 months later.

Of 763 non-industry interventional studies with no phase under Schizophrenia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 56. This study's planned 0 months is below that.

Counting every sponsor, half of 776 studies reached it within 32 months; a quarter within 16 and three quarters within 56.

Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Oct 2026, on Oct 28, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2026
First posted
Jul 14, 2026
StartEst.
Oct 26, 2026was Jul 2026
Primary completionEst.
Oct 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jul 6, 2026→Oct 26, 2026
Oct 28, 2026
Primary outcomes
2 time frame changed, 2 description edited
What changed in the outcomes
  • Time frameWorking Memory AccuracyDay 1 (baseline, prior to first intervention); within 15 minutes after Session 1; Day 9 (prior to second intervention, after 7-day washout); within 15 minutes after Session 2. → Day 1 (baseline, before the first intervention, during the intervention, and within 15 minutes after the intervention); Day 9 (before the second intervention, during the intervention, and within 15 minutes after the intervention).
  • Time frameWorking Memory Reaction TimeDay 1 (baseline, prior to first intervention); within 15 minutes after Session 1; Day 9 (prior to second intervention, after 7-day washout); within 15 minutes after Session 2. → Day 1 (baseline, before the first intervention, during the intervention, and within 15 minutes after the intervention); Day 9 (before the second intervention, during the intervention, and within 15 minutes after the intervention).
  • DescriptionWorking Memory Accuracy: how it is measured was reworded
  • DescriptionWorking Memory Reaction Time: how it is measured was reworded
Oct 28, 2026
Secondary outcomes
1 edited, 1 added
What changed in the outcomes
  • EditedHallucination and Delusion Visual Analog Scale (HD-VAS) ScoreTime frame: Within 15 minutes after completion of Session 1; within 15 minutes after completion of Session 2. → Within 15 minutes before and after completion of Session 1; within 15 minutes before and after completion of Session 2.
  • AddedDelusion Visual Analog ScaleTime frame: Within 15 minutes before and after completion of Session 1; within 15 minutes before and after completion of Session 2.
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Start date Jul 6, 2026→Oct 26, 2026
    Primary outcomes 2 time frame changed, 2 description edited
    What changed in the outcomes
    • Time frameWorking Memory AccuracyDay 1 (baseline, prior to first intervention); within 15 minutes after Session 1; Day 9 (prior to second intervention, after 7-day washout); within 15 minutes after Session 2. → Day 1 (baseline, before the first intervention, during the intervention, and within 15 minutes after the intervention); Day 9 (before the second intervention, during the intervention, and within 15 minutes after the intervention).
    • Time frameWorking Memory Reaction TimeDay 1 (baseline, prior to first intervention); within 15 minutes after Session 1; Day 9 (prior to second intervention, after 7-day washout); within 15 minutes after Session 2. → Day 1 (baseline, before the first intervention, during the intervention, and within 15 minutes after the intervention); Day 9 (before the second intervention, during the intervention, and within 15 minutes after the intervention).
    • DescriptionWorking Memory Accuracy: how it is measured was reworded
    • DescriptionWorking Memory Reaction Time: how it is measured was reworded
    Secondary outcomes 1 edited, 1 added
    What changed in the outcomes
    • EditedHallucination and Delusion Visual Analog Scale (HD-VAS) ScoreTime frame: Within 15 minutes after completion of Session 1; within 15 minutes after completion of Session 2. → Within 15 minutes before and after completion of Session 1; within 15 minutes before and after completion of Session 2.
    • AddedDelusion Visual Analog ScaleTime frame: Within 15 minutes before and after completion of Session 1; within 15 minutes before and after completion of Session 2.

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07701343
Responsible party
Renrong Wu (Professor, Second Xiangya Hospital of Central South University) — Principal investigator
First posted
Jul 14, 2026
Start date
Oct 26, 2026 (estimated)
Primary completion
Oct 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Oct 28, 2026

Study contacts

Renrong Wu
Contact
wurenrong@csu.edu.cn
15874179855

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion